BTK and mantle cell lymphoma: Even though Ibrutinib has shown an overall response rate of 68% (7), approximately 30% of MCL patients display a primary resistance to the drug, maybe due to a lack of normal BTK expression or presence of mutated BTK (5, 8, 9).